Flavone acetic acid (FAA), 8.6gm 2 has been administered by 6 h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in either disease.
FAA is the second of a series of compounds based on the flavonoid aglycone ring structure to undergo clinical evaluation in malignant disease. The parent compound (flavone acetic acid ester; LM985) was not recommended for phase II assessment because of drug associated acute hypotension and the fact that it appeared to function as a prodrug with rapid hydrolysis in vivo to FAA (Kerr et al., 1986) .
Preclinical studies with FAA indicate that it is active against a broad spectrum of murine transplantable solid tumours which tend, on the whole, to be refractory to conventional cytotoxic agents. These included a range of colon adenocarcinomas, pancreatic ductal adenocarcinoma, mammary adenocarcinoma and Glasgow's osteosarcoma (Corbett et al., 1986; Zaharko et al., 1986) .
Precinical pharmacology (Zaharko et al., 1986 ) implied a plasma concentration threshold for activity and toxicity in mice and dogs, the plasma concentrations achieved in man in the phase I study were similar to those which were active in murine tumour models. Clinical phase I trials were conducted using both 1 h and 6 h infusions given weekly. At maximum tolerated doses -6.4 gm-2 over I h and 10 g m-2 over 6 h -toxicity included hypotension, diarrhoea and intolerable warmth and flushing (Kerr et al., 1987) . A phase II trial programme has been planned in Europe using both I h (4.8 gm-2) and 6h (8.6gm-2) schedules. We report here a phase II Tables I and  II. Treatment associated toxicity is shown in Table III . Overall, the toxicity as reported was mild. However, two patients were withdrawn from the study, one with drug associated hypotension and the other with grade IV haematological toxicity. The first patient had a drop in systolic blood pressure from 130 to 85 mmHg, I h after the second infusion commenced. The drug infusion was stopped and his blood pressure returned to normal after 1.5h and no further drug treatment was given. The second patient had an episode of profound thrombocytopenia which developed shortly after her fifth cycle of FAA. Her platelet count fell to 1,000mm-3, she had spontaneous vaginal bleeding and required platelet transfusion. The patient recovered and subsequent investigations identified 1 gG and I gM antibodies to FAA on the patient's platelets. She had previously been treated in another study with a monoclonal antibody directed against carcino embryonic antigen and she had developed antimouse antibodies (Davis et al., 1988) . In terms Br. J. Cancer (I989), 60, [104] [105] [106] of chronic toxicity, one female patient with colorectal cancer developed severe persistent postural hypotension after completing treatment. Investigations performed in the MRC Blood Pressure Unit, Western Infirmary, Glasgow, indicated that she had developed an autonomic neuropathy presumably related to FAA treatment (Lewis et al., 1988) . She had good symptomatic control with fludriocortisone.
In terms of disease response, 13 of the melanoma patients progressed on treatment and one had stable disease at the end of treatment. Nine of the evaluable colorectal patients progressed on treatment and six had stable disease at the end of treatment.
Despite promising preclinical activity, FAA (8.6gm2 over 6 h) has no demonstrable clinical activity in advanced malignant melanoma and colorectal carcinoma. This result is similar to that reported by the Early Clinical Trials Group of the EORTC who found no activity in phase II trials in four tumour types using 4.8 g m 2 over 1 h (Kaye et al., 1989) . In the phase I trial, the pharmacokinetic profiles indicated that 'effective drug exposure', as assessed by the area under the plasma concentration time curve >lOOpgml-F, was approxcimately 50% greater for the 6h infusion. Despite this apparent pharmacokinetic advantage, the 6h infusion is also clinically inactive.
The toxicity associated with the phase II tnrals was similar to that predicted by the phase I trial. One patient suffered persistent toxicity in the form of postural hypotension caused by autonomic neuropathy, presumably related to treatment with FAA (Lewis et al., 1988) but no other 'late' toxicity has been seen.
The mechanism of action of FAA is unknown. There is only minimal damage to DNA, as assessed by alkaline elution (Bissery et al., 1988) . However, there is some evidence to suggest the FAA can induce haemorrhagic necrosis in murine colonic tumours (Smith et al., 1987) and decrease blood flow in subcutaneously implanted Glasgow's osteosarcoma as demonstrated by 31P nuclear magnetic response spectroscopy (Evelhoch et al., 1988) . In view of the clinical effects of FAA on blood pressure it is tantalising to hypothesise that differences in the regulation of tumour and systemic blood flow, between mouse and man, could contribute to FAA's inactivity clinically. In addition, FAA systemically augments natural killer cell activity in normal and tumour bearing mice and in human cancer patients, possibly by induction of z and P interferon (Horning et al., 1988) 
